Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01269346 · ClinicalTrials.gov registry record · Phase 2
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT01269346 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 52 participants.
The verdict
NCT01269346, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
This is a multicenter phase 2 study designed to evaluate the safety and efficacy of eribulin mesylate in combination with trastuzumab as first line treatment in female subjects with locally recurrent or metastatic human epidermal growth factor receptor (HER2) positive breast cancer.
Interventions
- DRUG Eribulin Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-12 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01269346
The ClinicalTrials.gov registry entry for NCT01269346 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eribulin Mesylate is the first listed.
NCT01269346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01269346 about?
NCT01269346 is a clinical study titled "Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer". This is a multicenter phase 2 study designed to evaluate the safety and efficacy of eribulin mesylate in combination with trastuzumab as first line treatment in female subjects with locally recurrent or metastatic human epidermal growth factor receptor (HER2) positive breast cancer.
What is the current status of trial NCT01269346?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2010-12. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01269346?
The interventions under investigation include: Eribulin Mesylate (DRUG).
Who is sponsoring clinical trial NCT01269346?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.